ArticleCell chemical biology2020
Expanding the Degradable Proteome: Designing PROTACs by the Book.
Article in Cell chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Degradation of G-quadruplex-binding proteins in chromatin using G4-ligand-based proteolysis-targeting chimeras.Nature chemistry · 2026Article
- Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants.Chemical communications (Cambridge, England) · 2021Article
- PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.Frontiers in pharmacology · 2021Review
- Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin.ChemMedChem · 2020Review
- Chemically Induced Degradation of WEE1 Kinase for Difficult to Treat Diseases.ACS medicinal chemistry letters · 2020Article
- Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.Trends in pharmacological sciences · 2020Review
- Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets.Cancer management and research · 2020Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this issue of Cell Chemical Biology, Li et al. (2020), Hsu et al. (2020), and Potjewyd et al. (2020) expand the target spectrum amenable to protein degradation by designing degraders of the cell cycle checkpoint kinase Wee1 and the polycomb repressive complex 2 (PRC2) via its regulatory EED subunit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.